Setipiprant for Androgenetic Alopecia in Males: Results from a Randomized, Double-Blind, Placebo-Controlled Phase 2a Trial

    Janet DuBois, Suzanne Bruce, Daniel Stewart … Joan-En Chang-Lin
    Studysummary This study found that oral setipiprant was safe but did not improve scalp hair growth compared to placebo in men with androgenetic alopecia.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on dovepress.com →
    Discuss this study in the Community →

    Research cited in this study 17

    1. Safety Concerns When Using Novel Medications to Treat Alopecia Expert Opinion on Drug Safety · 2018
    2. Evidence-Based Guideline for the Treatment of Androgenetic Alopecia in Women and Men – Short Version Journal of The European Academy of Dermatology and Venereology · 2017
    3. Multi-Therapies in Androgenetic Alopecia: Review and Clinical Experiences Dermatologic Therapy · 2016
    4. Does Prostaglandin D2 Hold the Cure to Male Pattern Baldness? Experimental Dermatology · 2014
    5. A Randomized, Active- and Placebo-Controlled Study of the Efficacy and Safety of Different Doses of Dutasteride Versus Placebo and Finasteride in the Treatment of Male Subjects with Androgenetic Alopecia Journal of The American Academy of Dermatology · 2014
    6. Prostaglandin D2 Inhibits Wound-Induced Hair Follicle Neogenesis Through the Receptor Gpr44 Journal of Investigative Dermatology · 2012
    7. The Prostamide-Related Glaucoma Therapy, Bimatoprost, Offers a Novel Approach for Treating Scalp Alopecias The FASEB Journal · 2012
    8. Prostaglandin D2 Inhibits Hair Growth and Is Elevated in Bald Scalp of Men with Androgenetic Alopecia Science Translational Medicine · 2012
    9. Efficacy and Safety of Finasteride Therapy for Androgenetic Alopecia Archives of Dermatology · 2010
    10. Male Androgenetic Alopecia Expert Opinion on Pharmacotherapy · 2010
    11. The Importance of Dual 5α-Reductase Inhibition in the Treatment of Male Pattern Hair Loss: Results of a Randomized Placebo-Controlled Study of Dutasteride Versus Finasteride Journal of The American Academy of Dermatology · 2006
    12. Psychological Effect, Pathophysiology, and Management of Androgenetic Alopecia in Men Mayo Clinic Proceedings · 2005
    13. A Randomized Clinical Trial of 5% Topical Minoxidil Versus 2% Topical Minoxidil and Placebo in the Treatment of Androgenetic Alopecia in Men Journal of The American Academy of Dermatology · 2002
    14. Prostaglandin-Induced Hair Growth Survey of Ophthalmology · 2002
    15. Clinical Dose Ranging Studies with Finasteride, a Type 2 5α-Reductase Inhibitor, in Men with Male Pattern Hair Loss Journal of The American Academy of Dermatology · 1999
    16. Finasteride, a Type 2 5α-Reductase Inhibitor, in the Treatment of Men with Androgenetic Alopecia Expert Opinion on Investigational Drugs · 1999
    17. The Psychological Effects of Androgenetic Alopecia in Men Journal of The American Academy of Dermatology · 1992

    Related research 1

    1. Progression of Hair Loss in Men With Androgenetic Alopecia: Long-Term Controlled Observational Data in Placebo-Treated Patients 2008